Rosiptor
Based on 3 publication(s) in Google Scholar
Rosiptor (AQX-1125) is a selective and orally active phosphatase SHIP1 activator with anti-inflammatory effects. Rosiptor (AQX-1125) inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro.
For research use only. We do not sell to patients.
- Purity : 99.73%
- CAS No.: 782487-28-9
- Formula: C20H35NO2
- Molecular Weight:321.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
SHIP1[1]
In Vitro
Rosiptor (0.1-10 μM; 30 minutes) inhibits Akt activation in MOLT-4, but not in Jurkat cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MOLT-4 cells and SHIP1-deficient Jurkat cells (IGF-1 stimulation)
-
Concentration:0.1, 1, 10 μM
-
Incubation Time:30 minutes
-
Result:Induced a concentration-dependent decrease in Akt phosphorylation in MOLT-4 cells, while it failed to affect Akt phosphorylation in Jurkat cells.
In Vivo
Rosiptor (10 mg/kg; p.o.) has the Cmax value of 0.830 μM and the t1/2 value of 5.2 hours. AQX-1125 also exhibits >80% oral bioavailability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 weeks old male CD-1 mice[1]
-
Dosage:3, 10, 30 mg/kg
-
Administration:p.o.; daily for 3 days
-
Result:Significantly reduced the total number of BAL leukocytes in NSC-125066-challenged mice, up to a maximum of 60% at 7 days and 63% at 21 days at 30 mg/kg; Reduced MPO activity by 54% at Day 7 and by 74% at Day 21 at 30 mg/kg.
-
Animal Model:Male Sprague-Dawley rats[1]
-
Dosage:10 mg/kg (Pharmacokinetic Study)
-
Administration:Oral administration
-
Result:The Cmax value is 0.830 μM and the t1/2 value is 5.2 hours.
- Kinase activity and phosphorylation assays
- Western Blot
- Cell migration
- Zigmond Chamber Chemotaxis Assay
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- Research Protocol for Inflammation-related Diseases
- Protocol for Kinase activity and phosphorylation assays
- Dunn/Insall Chamber Chemotaxis Assay
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 782487-28-9
-
Appearance Solid
-
Molecular Weight 321.50
-
Formula C20H35NO2
-
Color White to off-white
-
SMILES
C[C@@]([C@H]1CO)(CC[C@H](O)C1)[C@](CC[C@@]2(C)[C@@]3([H])CCC2=C)([H])[C@H]3CN
-
Synonyms
AQX-1125
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Front Cell Dev Biol
SHIP1 Activator AQX-1125 Regulates Osteogenesis and Osteoclastogenesis Through PI3K/Akt and NF-κb Signaling. [Abstract]2022 Apr 4;10:826023. PMID: 35445030 -
Antiviral Res
SHIP-1 affects herpetic simplex keratitis prognosis by mediating CD4+ T lymphocytes migration through PI3K signaling and transcription factor KLF2 in the cornea. [Abstract]2022 Nov:207:105424. PMID: 36155071 -
Cell Biol Int
Effective inhibition of miR-330/SHIP1/NF-κB signaling pathway via miR-330 sponge repolarizes microglia differentiation. [Abstract]2021 Apr;45(4):785-794. PMID: 33325083
Solvent & Solubility
In Vitro:
DMSO : 150 mg/mL (466.56 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
References
[1]. Stenton GR, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013 Mar;168(6):1506-18. [Content Brief]
[2]. Cross J, et al. AQX-1125, small molecule SHIP1 activator inhibits NSC-125066-induced pulmonary fibrosis. Br J Pharmacol. 2017 Sep;174(18):3045-3057. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1104 mL | 15.5521 mL | 31.1042 mL | 77.7605 mL |
| 5 mM | 0.6221 mL | 3.1104 mL | 6.2208 mL | 15.5521 mL | |
| 10 mM | 0.3110 mL | 1.5552 mL | 3.1104 mL | 7.7760 mL | |
| 15 mM | 0.2074 mL | 1.0368 mL | 2.0736 mL | 5.1840 mL | |
| 20 mM | 0.1555 mL | 0.7776 mL | 1.5552 mL | 3.8880 mL | |
| 25 mM | 0.1244 mL | 0.6221 mL | 1.2442 mL | 3.1104 mL | |
| 30 mM | 0.1037 mL | 0.5184 mL | 1.0368 mL | 2.5920 mL | |
| 40 mM | 0.0778 mL | 0.3888 mL | 0.7776 mL | 1.9440 mL | |
| 50 mM | 0.0622 mL | 0.3110 mL | 0.6221 mL | 1.5552 mL | |
| 60 mM | 0.0518 mL | 0.2592 mL | 0.5184 mL | 1.2960 mL | |
| 80 mM | 0.0389 mL | 0.1944 mL | 0.3888 mL | 0.9720 mL | |
| 100 mM | 0.0311 mL | 0.1555 mL | 0.3110 mL | 0.7776 mL |